Riskpilot← Back to searchSign inGet full accessSortina pharma AB
ABActiveOrg 5592354871Erik Dahlbergsgatan 11 AResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20201 employees
Revenue 2024
SEK 0
EBITDA margin
—
-65% vs 2023
Equity ratio
87.6%
Financial strength
Net profit 2024
SEK -1,1M
-27% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -1,1M | -65% |
| Net profit | SEK -1,1M | -27% |
| Total assets | SEK 7,3M | +24% |
| Equity | SEK 6,4M | +17% |
| Employees | 1 | — |
Legal name
Sortina pharma AB
Org number
5592354871
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
7 januari 2020
Share capital
SEK 31 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av en av ledamöterna i förening med suppleanten Firman tecknas av en av ledamöterna i förening med Rost, Sara Johanna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva utveckling syftande till kommersiell exploatering av nya behandlingsmetoder inom medicin, bland annat cancer-området och därmed förenlig verksamhet.
Address
Erik Dahlbergsgatan 11 A
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −21 | −88 | −409 | −678 | −1 120 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −21 | −88 | −409 | −678 | −1 120 |
| Net financials | — | −200 | −220 | −211 | −7 |
| Profit before tax | −21 | −288 | −629 | −889 | −1 127 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −21 | −288 | −629 | −889 | −1 127 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 458 | 2 323 | 4 451 | 5 884 | 7 292 |
| Equity | 104 | −184 | 1 868 | 5 435 | 6 385 |
| Long-term debt | 2 000 | 2 000 | 2 000 | 263 | 657 |
| Short-term debt | 354 | 506 | 584 | 186 | 251 |
| Total debt | 2 354 | 2 506 | 2 584 | 449 | 908 |
EBITDA margin
-112000000.0%
This company
15.8%
Market median
-708860859% vs market
20202024
Equity ratio
87.6%
This company
38.2%
Market median
+129% vs market
20202024
Return on equity
-17.7%
This company
18.4%
Market median
-196% vs market
20202024
Net profit margin
-112700000.0%
This company
8.1%
Market median
-1391358125% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.14×
This company
0.62×
Market median
+77% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SJ Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
KE | Audit | 2023 | — | — |
ZM Chief Auditor | Chief Auditor | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2023 | — | — | |
| Chairman | 2020 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2021 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2023 | — | — | |
| Deputy Board Member | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Sortina pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sara Johanna Rost | Chief Executive Officer | 0 companies |
| Karin Elisabeth Hammarberg | Audit | 0 companies |
| Zlatan Mitrovic | Chief Auditor | 0 companies |
| Klementina Österberg | Deputy Board Member | 0 companies |
| M H Charlotte Wiberg Larsson | Chairman | 0 companies |
| Per Jesper Dahlberg | Deputy Board Member | 0 companies |
| Bo Torsten Nilsson | Board of Directors | 0 companies |
| Peter Prosper A. Suenaert | Board of Directors | 0 companies |
| Bengt Anders Waas | Chairman | 0 companies |
| Eva Catharina Bäärnhielm Marklund | Board of Directors | 0 companies |
| Jan Roland Pilebjer | Board of Directors | 0 companies |
| Peter Jonas Michael Carlborg | Deputy Board Member | 0 companies |
| Tommy Ingemar Abrahamsson | Board of Directors | 0 companies |
| Göran Landberg | Board of Directors | 0 companies |
| Sara Johanna Kristina Malcus | Chairman | 0 companies |
| Bo Torsten Patrik Nilsson | Deputy Board Member | 0 companies |